AN2 Therapeutics

AN2 Therapeutics is a biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics derived from their boron chemistry platform. Their focus is on addressing rare, chronic, and serious infectious diseases with a high unmet need, including Chagas disease, NTM lung disease, and melioidosis. Their boron-based compounds are designed to be best-in-class therapeutics, offering unique advantages over traditional carbon-based molecules. AN2 Therapeutics is committed to advancing global health initiatives by leveraging non-dilutive funding from public and private sources.

They are currently conducting clinical trials for their investigational drugs, with a particular emphasis on epetraborole, which has shown promising results for the treatment of treatment-refractory Mycobacterium avium complex (MAC) lung disease. AN2 Therapeutics is a company dedicated to innovation in the field of infectious diseases, striving to create a positive impact on patient care and public health worldwide.

AN2 Therapeutics offers a competitive salary and bonus program, an equity incentive plan, and a comprehensive benefits package. The company provides flexible paid time off including holidays and sick days, as well as life and AD&D insurance, an employee assistance program, and short- and long-term disability. However, there is no information provided about remote work options or schedule flexibility.

AN2 Therapeutics offers a competitive and comprehensive benefits package to its employees and their families. These benefits include competitive salary and bonus program, an equity incentive plan, medical, dental, and vision insurance, a 401K retirement plan, flexible paid time off including holidays and sick days, life and AD&D insurance, an employee assistance program, and short- and long-term disability.

AN2 Therapeutics is a biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Their mission is to address the challenges of rare, chronic, and serious infectious diseases, particularly in areas of high unmet need, and to improve global human health. They strive to develop innovative therapies that are both safe and effective, working collaboratively with stakeholders to achieve their ambitious goals.

AN2 Therapeutics promotes a culture of collaboration, transparency, and respect, focused on driving the development of new treatments for infectious diseases and oncology. They are passionate about addressing global health challenges, empowering their team members to grow and develop, and embracing diversity, equity, and inclusion as fundamental values that strengthen their team and business.

AN2 Therapeutics values diversity, equity, and inclusion as fundamental to a strong team and business. They believe in creating a culture where employees feel empowered to grow and develop, are treated with respect and integrity, and where decisions are made with the patient at the forefront. This commitment to diversity, equity, and inclusion is reflected in their core values, which emphasize transparency, collaboration, adaptability, and innovation.